Ozon Pharmaceuticals raised 2.8 billion rubles following SPO

The shares of institutional investors and individuals in the total SPO volume amounted to 63% and 37%, respectively. In the future, Ozon Pharmaceuticals plans to conduct an additional issue of shares by open subscription; the cost of the securities has not yet been determined, but it will depend on the sales figures during the secondary offering. For all shareholders, the company will set the cost of participation in the additional issue, as with the SPO.

The pharmaceutical manufacturer announced the SPO on June 17. At that time, the company announced plans to sell from 55 million to 82 million shares, which corresponds to 5-7.5% of the total number of securities placed by Ozon Pharmaceuticals. The total share of the company's shares in free circulation was to increase to 15.4% after the SPO. The share offering itself was conducted through Ozon LLC, a subsidiary of the pharmaceutical manufacturer.

In October 2024, Ozon Pharmaceuticals announced a successful initial public offering (IPO) on the Moscow Exchange. The price of one security was 35 rubles, and the company raised a total of 3.45 billion rubles during the IPO. The company's market capitalization was then estimated at 38.5 billion rubles.

Ozon Pharmaceuticals was registered in 2012 in Tolyatti. According to SPARK-Interfax, in 2024 the company's revenue was 2.9 billion rubles, net profit - 2.2 billion rubles. The owners of the legal entity are 12 Russian citizens, who exactly is not specified. The company specializes in the production of generics on its own industrial lines. The founder and chairman of the board of directors of the company is Pavel Aleksenko.